Detail akcie Provectus Biopharm online

Business Summary: Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Provectus Biopharmaceuticals Inc revenues decreased from $279K to $0K. Net loss increased 13% to $1.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Immunotherapy medicines segment loss increase of 14% to $1.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.00271 to -$0.00307.